Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates plasma LDL cholesterol (LDL-c) levels by promoting the degradation of liver LDL receptors (LDLRs). Antibodies that inhibit PCSK9 binding ...
Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed. These missiles, which should unerringly home in on the target and make it ...
Many pharmaceuticals work by targeting what are known as ''G-protein-coupled receptors''. In a new study, scientists describe how they have been able to predict how special molecules that can be used ...
Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...
Many pharmaceuticals work by targeting what are known as "G-protein-coupled receptors". In a new study, scientists from Uppsala University describe how they have been able to predict how special ...
Structural biologists at Cold Spring Harbor Laboratory (CSHL) and collaborators at Emory University have obtained important scientific results likely to advance efforts to develop new drugs targeting ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 20 (Sep. 25, 2001), pp. 11142-11147 (6 pages) In view of the observation that corticotropin-releasing ...
Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed. In the case of radiotherapy, these missiles, which should unerringly home ...
Many pharmaceuticals work by targeting what are known as "G-protein-coupled receptors". In a new study, scientists from Uppsala University describe how they have been able to predict how special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results